Trial reportAmerican journal of hematology2011
Plasma glial fibrillary acidic protein levels in children with sickle cell disease.
Trial report in American journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Guideline
- Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease.Proteomics. Clinical applications · 2014Pooled it
- GFAP-BDP as an acute diagnostic marker in traumatic brain injury: results from the prospective transforming research and clinical knowledge in traumatic brain injury study.Journal of neurotrauma · 2013Trial
- Exploratory factor analysis yields grouping of brain injury biomarkers significantly associated with outcomes in neonatal and pediatric ECMO.Scientific reports · 2024Article
- Neurofilament light chain: A potential biomarker for cerebrovascular disease in children with sickle cell anaemia.British journal of haematology · 2023Article
- Neurocognitive Changes in Sickle Cell Disease: A Comprehensive Review.Annals of neurosciences · 2022Review
- Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease.Proteomics. Clinical applications · 2021Article
- Higher Concentration of Plasma Glial Fibrillary Acidic Protein in Wilson Disease Patients with Neurological Manifestations.Movement disorders : official journal of the Movement Disorder Society · 2021Observational
- Considerations for Cannabis Use to Treat Pain in Sickle Cell Disease.Journal of clinical medicine · 2020Review
- Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence.Complementary therapies in medicine · 2020Review
- Brain-derived neurotrophic factor levels in pediatric sickle cell disease.Pediatric blood & cancer · 2020Article
- Vascular Instability and Neurological Morbidity in Sickle Cell Disease: An Integrative Framework.Frontiers in neurology · 2019Article
- Association of nadir oxygen delivery on cardiopulmonary bypass with serum glial fibrillary acid protein levels in paediatric heart surgery patients.Interactive cardiovascular and thoracic surgery · 2016Observational
- Glial fibrillary acidic protein as a biomarker for brain injury in neonatal CHD.Cardiology in the young · 2016Article
- Parent education and biologic factors influence on cognition in sickle cell anemia.American journal of hematology · 2014Article
- Thrombospondin-1 and L-selectin are associated with silent cerebral infarct in children with sickle cell anaemia.British journal of haematology · 2013Article
- Acute silent cerebral ischemic events in children with sickle cell anemia.JAMA neurology · 2013Article
- Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas.Journal of neuro-oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
To determine if glial fibrillary acidic protein (GFAP) is associated with brain injury in children with sickle cell disease (SCD), we measured plasma GFAP among cross-sectional groups of unselected children with SCD, subsets of children with SCD and normal brain MRI or MRI evidence of cerebral infarct, healthy pediatric controls, and adults with brain injury. Children with SCD had higher plasma GFAP than healthy pediatric controls (mean concentrations 0.14 ± 0.37 vs. 0.07 ± 0.08 ng/mL; P 5 0.003); also, 16.0% (16/100) of children with SCD and cerebral infarct had GFAP elevations above the 95th percentile of healthy pediatric controls (P 5 0.04). Although not statistically significant, children with SCD and cerebral infarct had more elevated GFAP levels than with SCD and no infarct (16/100, 16.0% vs. 14/168, 8.3%; P 5 0.07). Children with SCD and acute brain ischemia had a higher proportion of elevated GFAP than SCD children with normal MRI (3/6, 50% vs.8.3%; P 5 0.01). GFAP was associated with elevated systolic blood pressure in the preceding year and correlated positively with white blood cell count and negatively with age and performance IQ. Plasma GFAP is elevated among children with SCD and may be associated with subclinical brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.